As of 2024-12-15, the Relative Valuation of Intellia Therapeutics Inc (NTLA) is (192.14) USD. This relative valuation is based on P/E multiples. With the latest stock price at 12.90 USD, the upside of Intellia Therapeutics Inc based on Relative Valuation is -1589.4%.
The range of the Relative Valuation is (158.69) - (166.41) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 17.3x - 34.4x | 25.8x |
| Forward P/E multiples | 18.5x - 19.4x | 19.0x |
| Fair Price | (158.69) - (166.41) | (192.14) |
| Upside | -1330.1% - -1390.0% | -1589.4% |
| Date | P/E |
| 2024-12-13 | -1.50 |
| 2024-12-12 | -1.58 |
| 2024-12-11 | -1.64 |
| 2024-12-10 | -1.72 |
| 2024-12-09 | -1.70 |
| 2024-12-06 | -1.72 |
| 2024-12-05 | -1.59 |
| 2024-12-04 | -1.69 |
| 2024-12-03 | -1.71 |
| 2024-12-02 | -1.83 |
| 2024-11-29 | -1.82 |
| 2024-11-27 | -1.77 |
| 2024-11-26 | -1.72 |
| 2024-11-25 | -1.72 |
| 2024-11-22 | -1.67 |
| 2024-11-21 | -1.61 |
| 2024-11-20 | -1.53 |
| 2024-11-19 | -1.65 |
| 2024-11-18 | -1.65 |
| 2024-11-15 | -1.63 |
| 2024-11-14 | -1.76 |
| 2024-11-13 | -1.88 |
| 2024-11-12 | -1.94 |
| 2024-11-11 | -2.04 |
| 2024-11-08 | -1.95 |
| 2024-11-07 | -1.87 |
| 2024-11-06 | -1.87 |
| 2024-11-05 | -1.80 |
| 2024-11-04 | -1.77 |
| 2024-11-01 | -1.73 |
| 2024-10-31 | -1.66 |
| 2024-10-30 | -1.67 |
| 2024-10-29 | -1.75 |
| 2024-10-28 | -1.90 |
| 2024-10-25 | -1.86 |
| 2024-10-24 | -1.85 |
| 2024-10-23 | -2.32 |
| 2024-10-22 | -2.46 |
| 2024-10-21 | -2.41 |
| 2024-10-18 | -2.46 |
| 2024-10-17 | -2.45 |
| 2024-10-16 | -2.40 |
| 2024-10-15 | -2.28 |
| 2024-10-14 | -2.27 |
| 2024-10-11 | -2.17 |
| 2024-10-10 | -2.07 |
| 2024-10-09 | -2.06 |
| 2024-10-08 | -2.09 |
| 2024-10-07 | -2.08 |
| 2024-10-04 | -2.10 |